title: Hydrogen Sulfide: A Therapeutic Candidate for Fibrotic Disease?
abstract: Fibrotic diseases including chronic kidney disease, liver cirrhosis, idiopathic pulmonary fibrosis, and chronic disease account for 45% mortality in the developed countries and pose a great threat to the global health. Many great targets and molecules have been reported to be involved in the initiation and/or progression of fibrosis, among which inflammation and oxidative stress are well-recognized modulation targets. Hydrogen sulfide (H2S) is the third gasotransmitter with potent properties in inhibiting inflammation and oxidative stress in various organs. Recent evidence suggests that plasma H2S level is decreased in various animal models of fibrotic diseases and supplement of exogenous H2S is able to ameliorate fibrosis in the kidney, lung, liver, and heart. This leads us to propose that modulation of H2S production may represent a promising therapeutic venue for the treatment of a variety of fibrotic diseases. Here, we summarize and discuss the current data on the role and underlying mechanisms of H2S in fibrosis diseases related to heart, liver, kidney, and other organs.
authors.affiliation: Department of Nephrology, The Second Affiliated Hospital of Soochow University, Suzhou 215004, China.
authors.forename: Kai
authors.initials: K
authors.lastname: Song
authors.affiliation: Institute of Neuroscience, Soochow University, Suzhou 215123, China ; Department of Pharmacology, School of Pharmaceutical Science, Soochow University, Suzhou 215123, China.
authors.forename: Qian
authors.initials: Q
authors.lastname: Li
authors.affiliation: Department of Nephrology, The Second Affiliated Hospital of Soochow University, Suzhou 215004, China.
authors.forename: Xiao-Ya
authors.initials: XY
authors.lastname: Yin
authors.affiliation: Department of Nephrology, The Second Affiliated Hospital of Soochow University, Suzhou 215004, China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Lu
authors.affiliation: Institute of Neuroscience, Soochow University, Suzhou 215123, China.
authors.forename: Chun-Feng
authors.initials: CF
authors.lastname: Liu
authors.affiliation: Institute of Neuroscience, Soochow University, Suzhou 215123, China ; Department of Pharmacology, School of Pharmaceutical Science, Soochow University, Suzhou 215123, China.
authors.forename: Li-Fang
authors.initials: LF
authors.lastname: Hu
mesh_terms: D000933:Antifibrinolytic Agents / Q000627:therapeutic use*; D005355:Fibrosis; D006801:Humans; D006862:Hydrogen Sulfide / Q000627:therapeutic use*; D054990:Idiopathic Pulmonary Fibrosis / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008103:Liver Cirrhosis / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D016328:NF-kappa B / Q000378:metabolism; D051436:Renal Insufficiency, Chronic / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D015398:Signal Transduction
chemical_list: D000933:Antifibrinolytic Agents; D016328:NF-kappa B; D006862:Hydrogen Sulfide